Skip to main content

Retreatment with trastuzumab in Her2-positive metastatic breast cancer patients: a clinical study


To study the benefit of trastuzumab in monotherapy or combined with different chemotherapeutic agents in the treatment for Her2+ metastatic breast cancer (MBC) patients after progression on prior trastuzumab therapy.

Patients and methods

The clinical evolution of patients with Her2+ MBC diagnosed by IHC3+/FISH+, and treated with trastuzumab in several lines for the metastatic disease, has been studied retrospectively.


Twenty-four patients with Her2+ MBC were treated with several regimens containing trastuzumab alone or associated with chemotherapy and/or hormonotherapy. In the first line of treatment 12 RR (50%), 11 SD (45%), with a 95% clinical benefit, was observed. The patients received a second line obtaining 8 RR (33%), 15 SD (62%), with a clinical benefit of 95%. Seventeen patients were treated with a third line, 5 RR (29.4%) and 11 SD (64%) being observed, with a clinical benefit of 93%. Seven patients received a fourth line. In these, 2 RR and 4 SD, with a clinical benefit of 85%, were observed. Fifteen of the patients, with RE+, received hormonotherapy plus trastuzumab alone or with chemotherapy in one or more lines of treatment, obtaining 8 RR (53%) and 4 SD (26%), with a clinical benefit of 79%.


The association of herceptin with chemotherapy and/or hormonotherapy demonstrates a very active treatment in patients with Her2+ MBC. The benefit seems to continue in patients who already have received treatment with trastuzumab even in more than one regimen.

Author information

Authors and Affiliations


Rights and permissions

Reprints and Permissions

About this article

Cite this article

Carabantes-Ocón, F., Saez-Lara, E., Burgos-Garcia, L. et al. Retreatment with trastuzumab in Her2-positive metastatic breast cancer patients: a clinical study. Breast Cancer Res 9 (Suppl 1), SP2 (2007).

Download citation

  • Received:

  • Published:

  • DOI:


  • Breast Cancer
  • Cancer Patient
  • Clinical Study
  • Cancer Research
  • Breast Cancer Patient